SCHEMBL6970992

SCHEMBL6970992

O=C(N[C@H]1CCNC1)[C@@H]1CCCCN1c1nc2ccccc2o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 2/20 0.54
TSHR P16473 1/20 0.54
ELANE P08246 2/20 0.45
CHRNA7 P36544 1/20 0.44
HTR3A P46098 1/20 0.44
IGF1R P08069 1/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGES O14684 3/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6976210 1.00 LMNA (0.54) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6979378 0.94 LMNA (0.59) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL7846258 0.94 LMNA (0.59) LMNASMN1; SMN2MAPTHTTTSHR
Tert-Butyl Formate SCHEMBL27495904 0.85 LMNA (0.49) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL7680423 0.83 LMNA (0.58) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6974109 0.82 LMNA (0.53) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6972076 0.80 LMNA (0.52) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6971418 0.80 LMNA (0.54) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6975929 0.80 LMNA (0.52) LMNASMN1; SMN2MAPTHTTTSHR
SCHEMBL6968264 0.79 OPRK1 (0.56) LMNASMN1; SMN2MAPTHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562964-B1 Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders PFIZER INC 2003-05-13 US disclosed
EP-1100797-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LTD (GB) 2003-02-26 EP disclosed
US-6372736-B1 ENZYME INHIBITORS PFIZER INC 2002-04-16 US disclosed
EP-1100797-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES Pfizer Limited (GB) 2001-05-23 EP disclosed
WO-2000005232-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LIMITED (GB) 2000-02-03 WO disclosed